Side-by-side · Research reference

HGH 191AAvsMazdutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED0/75 cited

BPhase 3HUMAN-REVIEWED19/62 cited

HGH 191AA

Recombinant hGH · FDA-Approved

0.024–0.034 mg/kg/dayPediatric GHD dose

2–4 hoursPlasma half-life

191 AASequence length

SQ · Daily · Evening preferred

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

01Mechanism of Action

Parameter

HGH 191AA

Mazdutide

Primary target

Growth hormone receptor (GHR) — JAK2/STAT5 pathway

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Pathway

GHR activation → JAK2/STAT5 → liver IGF-1 synthesis + direct metabolic effects

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Downstream effect

Linear growth, lipolysis, protein synthesis, nitrogen retention, carbohydrate metabolism modulation

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Feedback intact?

No — exogenous GH bypasses hypothalamic-pituitary axis, suppresses endogenous pulsatility

Yes — physiological receptor-mediated signaling preserved

Origin

Recombinant DNA technology — 191 AA, identical to pituitary hGH, no methionyl residue

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Antibody development

Rare — <2% develop binding antibodies, typically non-neutralizing

—

02Dosage Protocols

Parameter

HGH 191AA

Mazdutide

Pediatric GHD

0.024–0.034 mg/kg/day SQ

6–7× per week dosing typical. Brand-specific ranges.

—

Adult GHD

0.004–0.016 mg/kg/day SQ

Start low, titrate based on IGF-1 levels.

—

Turner syndrome

0.045–0.050 mg/kg/day SQ

—

Idiopathic short stature

0.037 mg/kg/day SQ

—

AIDS wasting

0.1 mg/kg/day SQ (high-dose)

Short-term indication. Monitor glucose.

—

Frequency

Once daily, typically evening

Evening administration mimics physiological GH pulse.

Once weeklyJi 2026 Luo 2026

Evidence basis

FDA-approved / decades of RCT data

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Monitoring

IGF-1, glucose, thyroid function, bone age (children)

—

Duration

Years (children until epiphyseal closure); indefinite (adult GHD)

—

Phase 2 studied dose

—

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

Route

—

SubcutaneousJi 2026

Dose escalation

—

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

Duration (trials)

—

24–48 weeks

Population

—

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

Phase 3 comparator

—

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

03Metabolic / Fat Loss Evidence

Parameter

HGH 191AA

Mazdutide

Primary fat target

Visceral and subcutaneous adipose tissue

—

Mechanism

Lipolysis via hormone-sensitive lipase activation, FFA oxidation

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

Effect on lean mass

Significant lean mass increase (protein synthesis, nitrogen retention)

—

Insulin sensitivity

Acute insulin resistance (anti-insulin effect); chronic neutral-to-improved via fat loss

—

IGF-1 elevation

Dose-dependent, significant — primary anabolic mediator

—

Glucose metabolism

Hyperglycemia risk, especially high doses (AIDS wasting)

—

Body composition

↓ fat mass, ↑ lean mass, ↑ bone mineral density (children)

—

Clinical context

FDA-approved for AIDS wasting (cachexia). Off-label use for body recomposition lacks long-term safety data.

—

Percentage body weight loss

—

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

Absolute weight loss

—

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

Responder rate (≥10% loss)

—

Not explicitly reported in available abstracts

BMI reduction

—

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

Visceral fat

—

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

Glycemic improvement

—

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

Comparator efficacy

—

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

Key publications

—

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

04Side Effects & Safety

Parameter

HGH 191AA

Mazdutide

Injection site reaction

Lipohypertrophy, lipoatrophy, erythema (rotate sites)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel syndrome (dose-dependent)

—

Glucose intolerance

Hyperglycemia, new-onset diabetes (anti-insulin effect)

—

Intracranial hypertension

Benign intracranial hypertension (pseudotumor cerebri) — headache, visual changes, papilledema

—

Slipped capital femoral epiphysis

SCFE risk in children — limp, hip/knee pain (requires surgery)

—

Scoliosis progression

Rapid growth may unmask/progress scoliosis (monitor spine in children)

—

Hypothyroidism

Central hypothyroidism unmasking or worsening (monitor TSH, free T4)

—

Cancer risk

Contraindicated in active malignancy. Theoretical risk in cancer survivors (controversial).

—

Antibody formation

Rare (<2%), typically non-neutralizing. Loss of efficacy if neutralizing antibodies develop.

—

Pancreatitis

Rare. Higher risk in children with certain syndromes (Prader-Willi).

—

Gynecomastia

Adolescent males (physiological during puberty, may be exacerbated)

—

Gastrointestinal symptoms

—

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

Injection site reactions

—

Erythema, pruritus, local discomfort

Hypoglycemia

—

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

Cardiovascular effects

—

Increased heart rate (glucagon effect, transient)

Pancreatitis risk

—

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

Thyroid C-cell tumors

—

Black box warning for GLP-1 class (rodent data); human relevance unclear

Gallbladder disease

—

Cholelithiasis, cholecystitis (rapid weight loss effect)

Tolerability

—

Generally well-tolerated; GI effects diminish with dose titration

Absolute Contraindications

HGH 191AA

·Active malignancy or history of cancer (especially childhood cancer survivors with risk factors)
·Acute critical illness (post-cardiac surgery, trauma, acute respiratory failure)
·Diabetic retinopathy (active proliferative or severe non-proliferative)
·Prader-Willi syndrome with severe obesity, sleep apnea, or respiratory impairment
·Closed epiphyses (for growth indications)

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Relative Contraindications

HGH 191AA

·Diabetes mellitus (monitor closely, may require insulin adjustment)
·Intracranial lesions or history of intracranial hypertension
·Scoliosis (monitor curve progression)
·Untreated hypothyroidism (treat before GH initiation)
·Severe obesity (assess OSA risk, cardiovascular status)

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

05Administration Protocol

Parameter

HGH 191AA

Mazdutide

1. Reconstitution (if lyophilized)

Add diluent (sterile water or bacteriostatic water per manufacturer) to vial. Swirl gently — do not shake. Solution should be clear, colorless. Concentration varies by brand (e.g., 5 mg or 10 mg per vial).

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

2. Injection site

Subcutaneous — rotate sites: abdomen, thigh, buttocks, upper arm. Avoid same site within 1 cm for 2 weeks to prevent lipodystrophy.

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

3. Timing

Once daily, evening preferred (6–8 PM or pre-sleep). Mimics physiological nocturnal GH secretion. Consistency is critical.

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

4. Storage

Unreconstituted: refrigerate 2–8 °C, protect from light. Reconstituted: refrigerate, use within 14–28 days (brand-specific). Do not freeze.

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

5. Needle

27–31G, 4–8 mm insulin syringe or pen device. Pinch skin, 45–90° angle depending on subcutaneous thickness.

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

6. Monitoring

Baseline and periodic: IGF-1 (target age/sex-adjusted midrange), fasting glucose, HbA1c, thyroid function (TSH, free T4), bone age (children), lipid panel. Fundoscopy if headache/visual symptoms.

—

06Stack Synergy

HGH 191AA

+ Ipamorelin

Moderate

View Ipamorelin →

Ipamorelin (GHRP) stimulates endogenous GH release, which is redundant when exogenous rhGH is administered. However, ipamorelin may still amplify pulsatility of remaining endogenous secretion in partial GHD or during GH dose titration. Not typically combined in standard clinical practice; more common in experimental or off-label protocols. Limited evidence for additive benefit.

HGH 191AA: Standard dose per indication
Ipamorelin: 100–200 mcg SQ · morning (if used)
Note: Monitor IGF-1 closely; avoid supraphysiological levels
Primary benefit: Theoretical enhancement of pulsatility; limited clinical rationale

+ Tesamorelin

Weak

View Tesamorelin →

Tesamorelin (GHRH analogue) stimulates endogenous GH secretion, which is unnecessary when exogenous rhGH is already provided. Combining both offers no mechanistic advantage and increases cost, side effects, and IGF-1 elevation risk. Not recommended in clinical practice.

Note: Combination not recommended — choose one GH modality
Primary benefit: None — redundant mechanisms

Mazdutide

— no documented stacks